Avidity Biosciences Update to the Duchenne Community on Status of DMD45 Investigational Program

June 4, 2026

On June 4, 2026, Avidity Biosciences shared an update on the planned AOC 1045 clinical trial for individuals with
Duchenne muscular dystrophy amenable to exon 45 skipping (DMD45).

To view their Community Letter, please click here.

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA